J Rheum Dis.  2023 Jul;30(3):141-150. 10.4078/jrd.2023.0029.

Korean guidelines for the management of gout

• Lee JJ
• Lee JS
• Chung MK
• Ahn JK
• Choi HJ
• Hong SJ
• Yoon CH
• Kim SH
• Jeong KH
• Kim JW
• Kim BY
• Shin JH
• Kim WG
• Kim SY
• Kim HJ
• Song JS
• Jun JB
• Park HA
• Chae SC
• Choi BS
• Kim TN
• Kim HA

• KMID: 2543941
• DOI: http://doi.org/10.4078/jrd.2023.0029

Abstract

Gout is the most common form of arthritis, with the prevalence increasing worldwide. The present treatment guidelines provide recommendations for the appropriate treatment of acute gout, management during the inter-critical period, and prevention of chronic complications. The guidelines were developed based on evidence-based medicine and draft recommendations finalized after expert consensus. These guidelines are designed to provide clinicians with clinical evidence to enable efficient treatment of gout.

Keyword

Gout; Guidelines; Treatment

Reference

1. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. 2011; The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 343:d5928. DOI: 10.1136/bmj.d5928. PMID: 22008217. PMCID: PMC3196245.

2. Kim SY, Park JE, Lee YJ, Seo HJ, Sheen SS, Hahn S, et al. 2013; Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. J Clin Epidemiol. 66:408–14. DOI: 10.1016/j.jclinepi.2012.09.016. PMID: 23337781.

3. Schünemann H, Brożek J, Guyatt G, Oxman A. 2013; GRADE handbook. GRADE Working Group.

4. Andrews J, Guyatt G, Oxman AD, Alderson P, Dahm P, Falck-Ytter Y, et al. 2013; GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol. 66:719–25. DOI: 10.1016/j.jclinepi.2012.03.013. PMID: 23312392.

5. Chung MK, Kim SS, Cheon YH, Hong SJ, Choi HJ, Seo MR, et al. 2021; Patient perspectives and preferences regarding gout and gout management: impact on adherence. J Korean Med Sci. 36:e208. DOI: 10.3346/jkms.2021.36.e208. PMID: 34402226. PMCID: PMC8369315.

6. Alloway JA, Moriarty MJ, Hoogland YT, Nashel DJ. 1993; Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis. J Rheumatol. 20:111–3.

7. Billy CA, Lim RT, Ruospo M, Palmer SC, Strippoli GFM. 2018; Corticosteroid or nonsteroidal antiinflammatory drugs for the treatment of acute gout: a systematic review of randomized controlled trials. J Rheumatol. 45:128–36. DOI: 10.3899/jrheum.170137. PMID: 28765243.

8. Roddy E, Clarkson K, Blagojevic-Bucknall M, Mehta R, Oppong R, Avery A, et al. 2020; Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care. Ann Rheum Dis. 79:276–84. DOI: 10.1136/annrheumdis-2019-216154. PMID: 31666237. PMCID: PMC7025732.

9. Eminaga F, La-Crette J, Jones A, Abhishek A. 2016; Does the initiation of urate-lowering treatment during an acute gout attack prolong the current episode and precipitate recurrent attacks: a systematic literature review. Rheumatol Int. 36:1747–52. Erratum. DOI: 10.1007/s00296-016-3579-z. PMID: 27761603. PMCID: PMC5102948.

10. Feng X, Li Y, Gao W. 2015; Significance of the initiation time of urate-lowering therapy in gout patients: a retrospective research. Joint Bone Spine. 82:428–31. DOI: 10.1016/j.jbspin.2015.02.021. PMID: 26456042.

11. Hill EM, Sky K, Sit M, Collamer A, Higgs J. 2015; Does starting allopurinol prolong acute treated gout? A randomized clinical trial. J Clin Rheumatol. 21:120–5. DOI: 10.1097/RHU.0000000000000235. PMID: 25807090.

12. Sun R, Lu J, Li H, Cheng X, Xin Y, Li C. 2020; Evaluation of febuxostat initiation during an acute gout attack: a prospective, randomized clinical trial. Joint Bone Spine. 87:461–6. DOI: 10.1016/j.jbspin.2020.03.017. PMID: 32302693.

13. Taylor TH, Mecchella JN, Larson RJ, Kerin KD, Mackenzie TA. 2012; Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. Am J Med. 125:1126–34.e7. DOI: 10.1016/j.amjmed.2012.05.025. PMID: 23098865.

14. Borstad GC, Bryant LR, Abel MP, Scroggie DA, Harris MD, Alloway JA. 2004; Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol. 31:2429–32.

15. Mitha E, Schumacher HR, Fouche L, Luo SF, Weinstein SP, Yancopoulos GD, et al. 2013; Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial. Rheumatology (Oxford). 52:1285–92. DOI: 10.1093/rheumatology/ket114. PMID: 23485476.

16. Paulus HE, Schlosstein LH, Godfrey RG, Klinenberg JR, Bluestone R. 1974; Prophylactic colchicine therapy of intercritical gout. A placebo-controlled study of probenecid-treated patients. Arthritis Rheum. 17:609–14. DOI: 10.1002/art.1780170517. PMID: 4606955.

17. Poiley J, Steinberg AS, Choi YJ, Davis CS, Martin RL, McWherter CA, et al. 2016; A randomized, double-blind, active- and placebo-controlled efficacy and safety study of arhalofenate for reducing flare in patients with gout. Arthritis Rheumatol. 68:2027–34. DOI: 10.1002/art.39684. PMID: 26989892. PMCID: PMC5129473.

18. Schlesinger N, Mysler E, Lin HY, De Meulemeester M, Rovensky J, Arulmani U, et al. 2011; Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis. 70:1264–71. DOI: 10.1136/ard.2010.144063. PMID: 21540198. PMCID: PMC3103669.

19. Schumacher HR Jr, Evans RR, Saag KG, Clower J, Jennings W, Weinstein SP, et al. 2012; Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. Arthritis Care Res (Hoboken). 64:1462–70. DOI: 10.1002/acr.21690. PMID: 22549879.

20. Schumacher HR Jr, Sundy JS, Terkeltaub R, Knapp HR, Mellis SJ, Stahl N, et al. 2012; Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 64:876–84. DOI: 10.1002/art.33412. PMID: 22223180.

21. Sundy JS, Schumacher HR, Kivitz A, Weinstein SP, Wu R, King-Davis S, et al. 2014; Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study. J Rheumatol. 41:1703–11. DOI: 10.3899/jrheum.131226. PMID: 25028379.

22. Yamanaka H, Tamaki S, Ide Y, Kim H, Inoue K, Sugimoto M, et al. 2018; Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study. Ann Rheum Dis. 77:270–6. DOI: 10.1136/annrheumdis-2017-211574. PMID: 29102957. PMCID: PMC5867413.

23. Solomon DH, Liu CC, Kuo IH, Zak A, Kim SC. 2016; Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims. Ann Rheum Dis. 75:1674–9. DOI: 10.1136/annrheumdis-2015-207984. PMID: 26582823. PMCID: PMC5049504.

24. Yu J, Qiu Q, Liang L, Yang X, Xu H. 2018; Prophylaxis of acute flares when initiating febuxostat for chronic gouty arthritis in a real-world clinical setting. Mod Rheumatol. 28:339–44. DOI: 10.1080/14397595.2017.1318467. PMID: 28485997.

25. Shiozawa A, Szabo SM, Bolzani A, Cheung A, Choi HK. 2017; Serum uric acid and the risk of incident and recurrent gout: a systematic review. J Rheumatol. 44:388–96. DOI: 10.3899/jrheum.160452. PMID: 28148699.

26. Joo K, Kwon SR, Lim MJ, Jung KH, Joo H, Park W. 2014; Prevention of comorbidity and acute attack of gout by uric acid lowering therapy. J Korean Med Sci. 29:657–61. DOI: 10.3346/jkms.2014.29.5.657. PMID: 24851021. PMCID: PMC4024939.

27. Latourte A, Bardin T, Clerson P, Ea HK, Flipo RM, Richette P. 2018; Dyslipidemia, alcohol consumption, and obesity as main factors associated with poor control of urate levels in patients receiving urate-lowering therapy. Arthritis Care Res (Hoboken). 70:918–24. DOI: 10.1002/acr.23347. PMID: 28834411.

28. Dalbeth N, Billington K, Doyle A, Frampton C, Tan P, Aati O, et al. 2019; Effects of allopurinol dose escalation on bone erosion and urate volume in gout: a dual-energy computed tomography imaging study within a randomized, controlled trial. Arthritis Rheumatol. 71:1739–46. DOI: 10.1002/art.40929. PMID: 31081595.

29. Araujo EG, Bayat S, Petsch C, Englbrecht M, Faustini F, Kleyer A, et al. 2015; Tophus resolution with pegloticase: a prospective dual-energy CT study. RMD Open. 1:e000075. DOI: 10.1136/rmdopen-2015-000075. PMID: 26509070. PMCID: PMC4613163.

30. Villaverde V, Rosario MP, Loza E, Pérez F. 2014; Systematic review of the value of ultrasound and magnetic resonance musculoskeletal imaging in the evaluation of response to treatment of gout. Reumatol Clin. 10:160–3. DOI: 10.1016/j.reuma.2013.07.011. PMID: 24296268.

31. Hui M, Carr A, Cameron S, Davenport G, Doherty M, Forrester H, et al. 2017; The British Society for Rheumatology guideline for the management of gout. Rheumatology (Oxford). 56:e1–20. Erratum. DOI: 10.1093/rheumatology/kex156. PMID: 28549177.

32. Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, et al. 2017; 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 76:29–42. DOI: 10.1136/annrheumdis-2016-209707. PMID: 27457514.

33. Beslon V, Moreau P, Maruani A, Maisonneuve H, Giraudeau B, Fournier JP. 2018; Effects of discontinuation of urate-lowering therapy: a systematic review. J Gen Intern Med. 33:358–66. DOI: 10.1007/s11606-017-4233-5. PMID: 29204974. PMCID: PMC5834964.

34. Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. 2002; Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum. 47:356–60. DOI: 10.1002/art.10511. PMID: 12209479.

35. Borghi C, Rosei EA, Bardin T, Dawson J, Dominiczak A, Kielstein JT, et al. 2015; Serum uric acid and the risk of cardiovascular and renal disease. J Hypertens. 33:1729–41. DOI: 10.1097/HJH.0000000000000701. PMID: 26136207.

36. Suliman ME, Johnson RJ, García-López E, Qureshi AR, Molinaei H, Carrero JJ, et al. 2006; J-shaped mortality relationship for uric acid in CKD. Am J Kidney Dis. 48:761–71. DOI: 10.1053/j.ajkd.2006.08.019. PMID: 17059995.

37. Wang H, Wei Y, Kong X, Xu D. 2013; Effects of urate-lowering therapy in hyperuricemia on slowing the progression of renal function: a meta-analysis. J Ren Nutr. 23:389–96. DOI: 10.1053/j.jrn.2012.08.005. PMID: 23131573.

38. Kim S, Kim HJ, Ahn HS, Oh SW, Han KH, Um TH, et al. 2017; Renoprotective effects of febuxostat compared with allopurinol in patients with hyperuricemia: a systematic review and meta-analysis. Kidney Res Clin Pract. 36:274–81. DOI: 10.23876/j.krcp.2017.36.3.274. PMID: 28904879. PMCID: PMC5592895.